sosou
24小时客服热线 029-88323296

当前位置:

首页 >微创学院 >聚桂醇文献

文献推荐 | 聚多卡醇预处理增强HIFU治疗T2高信号子宫肌瘤聚桂醇文献

发布时间:2026-10-16 17:15:50 来源: 浏览次数:104

《International Journal  of  Hyperthermia》

2026, VOL. 43,  NO.  1,  2612543

Polidocanol  augments  high-intensity focused  ultrasound  efficacy for hyperintense fibroids  on T2WI:  a  retrospective  cohort  study

Ming-tao Yang,  Ling Tian, Yu  Xia,  Hong-ni  He,  Chuan  Lin, Tian-wen  He, Ying Tang , Hui-quan  Hu  and Jun  Li

Department of Obstetrics and Gynecology, The Second Clinical  Medical College of North Sichuan  Medical College,  Nanchong, Sichuan, China

 

ABSTRACT:

Objective:  To  compare  the  immediate  efficacy  and  safety  of  high-intensity  focused ultrasound (HIFU) monotherapy with the combination of ultrasound-guided intratumoral polidocanol   injection   and   HIFU   for   the   treatment   of   uterine   fibroids   with   highT2-weighted imaging  (T2WI) signal  intensity.

 

Methods:  In this retrospective study,  116 patients with T2-hyperintense uterine fibroids treated between January 2024 and May 2025 were enrolled.  Patients were allocated to either  HIFU  monotherapy  (the  H  group,  n =63)  or  combined  polidocanol  and  HIFU therapy  (the  H +P  group,  n =53). Thereafter,  therapeutic  parameters,  the  non-perfused volume ratio (NPVR), and adverse events were compared between the two groups after propensity score  matching.

 

Results: The  matched cohort comprised 53  patients  per group. The  median  NPVR was significantly higher in the H +P group than in the H group (92.57% vs. 77.81%, p <0.001). Additionally,  a  significantly  greater  proportion  of  patients  in the  H +P  group  achieved an  NPVR  ≥  80%  (87% vs. 43%, p <0.001)  and  an  NPVR  ≥  90%  (60% vs.  9%, p <0.001). The  H +P group also  required significantly  less sonication time and  lower total energy delivery (both p <0.05). Furthermore, the overall incidence of adverse events was similar between the two groups (73.6% vs. 69.8%, p =0.506). However, the H +P group exhibited a  markedly  lower incidence of sacrococcygeal  pain  (5.7% vs. 45.3%, p <0.001). 

Conclusion:   Pretreatment  with  ultrasound-guided  intratumoral  polidocanol  injection may   improve   the   immediate   ablation   efficacy   of   HIFU   in  T2-hyperintense   uterine fibroids, reducing energy requirements and mitigating procedure-related sacrococcygeal pain. These findings  highlight  the  potential  of this  combined  therapy  and  underscore the  need for  prospective studies to confirm its  long-term clinical  benefits.

KEYWORDS High-intensity focused ultrasound; polidocanol;hyperintense fibroids on T2WI;  uterine fibroids;efficacy

Introduction

Uterine fibroids are the  most common  benign tumors  in women of reproductive age, with a  prevalence rate  of 20%–77%  [1]. Approximately  30%-50%  of patients  present with  symptoms  such  as  menorrhagia, pelvic  pain, and frequent  urination, significantly  impairing their quality of life  [2].

High-intensity focused  ultrasound  (HIFU), as a  noninvasive thermal ablation technique,  induces tumor necrosis  through  the  precisely  focused  ultrasound  waves,  which  offers  advantages  such  as  minimal trauma and  rapid  recovery  [3].  It  has  become a  preferred treatment  option for  patients  desiring fertility preservation or those seeking to avoid surgery [4]. HIFU works by concentrating ultrasonic energy on the target  lesion, causing coagulative  necrosis in the fibroid tissue.  However, the characteristics of the target medium may affect ultrasound energy deposition, thereby affecting the therapeutic efficacy. Recent studies have highlighted that MRI T2-weighted imaging (T2WI) signal intensity is the most critical influencing factor  for  ablation  efficiency  [5].  Fibroids  with high T2  signal intensity posesignificantly  greater  clinical challenges   than   those   with   low   or   isointense   signals   [6].   Their   tissue   properties   impede   energy deposition,  limiting the  HIFU  ablation  efficacy,  often  resulting  in  insufficient  nonperfused volume  (NPV) ratios (NPVRs) [7,8]. These limitations may hinder symptom relief and necessitate secondary interventions. Consequently, optimizing  protocols for  hyperintense fibroids on T2WI  has  become a  research  priority.

Recent  studies  have  suggested that combination therapies  may enhance the  HIFU  efficacy for  refractory  fibroids  [9–11].  Polidocanol,  as  a  sclerosing  agent,  reduces  lesion  blood  supply  through  vascular embolization and has been safely used in various conditions [12,13]. Ultrasound-guided Polidocanol-assisted radiofrequency  ablation  (RFA)  shows  clinical  value  for  vascular  subserosal  fibroids  [14].  Notably,  when mixed with air to form foam, Polidocanol may theoretically enhance cavitation and thermal effects during HIFU  [9,10,15].  However,  clinical  evidence  regarding  its  efficacy  specifically for fibroids with  high T2  signals  remains  limited.

Based on these theoretical advantages, our institution has implemented the combined Polidocanol-HIFU therapy  for  selected  hyperintense  fibroids  on  T2WI.  This  retrospective  study  aimed  to  compare  HIFU monotherapy with the combination of Polidocanol  pretreatment and  HIFU  in this challenging subgroup, and evaluate their  immediate efficacy and safety through  historical treatment data.

 

Materials and  methods

Study design and setting

This  single-center  retrospective  cohort  study  was  conducted  in  accordance  with  the  Strengthening  the Reporting  of  Observational  Studies  in  Epidemiology  (STROBE)  guidelines.  Historical  treatment  data  of patients  with  uterine  fibroids  treated  at  our  institution  between January  2024  and  May  2025  were  collected. Through  systematic  review  of  electronic  medical  records,  116  consecutive  patients  meeting  the following  criteria were  identified.  Inclusion  criteria:  (1)  reproductive-age women;  (2) those  showing  documented  preference  for  uterine  preservation;  (3)  having  single  fibroid  with  high T2  signal  intensity  on magnetic resonance imaging (MRI) (defined as signal intensity >myometrium [17]); and (4) with complete pre-  and  post-treatment  imaging  data.  Exclusion  criteria:  (1)  pregnant  or  breastfeeding women  (verified by   β-human   chorionic   gonadotropin   testing);   (2)   those   with   active   gynecological   pathologies   (e.g. histological-confirmed  malignancies, acute  pelvic inflammatory disease (PID)); (3) connective tissue disorders  (systemic  lupus,  scleroderma,  etc.);  (4)  MRI  evidence  of fibroid  degeneration  (necrosis  >  50%,  calcification,  red  degeneration);  (5)  recent  (<  6 months)  thromboembolic  or  hemorrhagic  events;  and  (6) severe  organ  dysfunction  (estimated  glomerular  filtration  rate  (eGFR)  <  30,  and  left  ventricular  ejection fraction  (LVEF)  < 40%, etc.). The  Ethics Committee of North Sichuan  Medical College granted exemption from informed consent (IRB:2025120), because only deidentified historical data were analyzed, in compliance with the  Declaration of Helsinki  principles.

 

Data collection and variables

Data  were  extracted  from  electronic  medical  records  by  two  independent  investigators  according  to  a standardized protocol. Variables collected included demographics: age and body mass index (BMI); fibroid characteristics: volume  (cm³),  location  (submucosal,  intramural, subserosal), and  position  (anterior,  posterior, lateral, fundal); MRI parameters: subcutaneous fat thickness (mm), fibroid-sacrococcyx distance (mm), and  T2WI  signal  intensity  (quantitative  region  of  interest  (ROI)  analysis);  ultrasound  parameters:  blood flow grade  (0–4 scale); treatment  parameters: sonication time, total energy, and treatment  intensity. Our outcomes were NPVR and adverse events. Based on the actual treatments received, patients were divided into   the   H   group   (n =63)   receiving   HIFU   monotherapy,   and   the   H +P   group   (n =53)   undergoing ultrasound-guided  intratumoral  polidocanol  injection combined with  HIFU.

 

Pre-HIFU MRI and ultrasound evaluation

MRI  examination  was  performed  using  the  GE  Signa  HDxt  1.5 T  superconducting  MRI  scanner.  Patients underwent  MRI  scans  within  three  days  before  HIFU  treatment  according  to  the  standardized  protocol. Based on the Funak criteria, fibroids were classified as hypointense, isointense, or hyperintense according to  the  T2WI  signal  intensity  [16].  Hyperintense  fibroids  on  T2WI  were  defined  as  those  with  signal intensity values  exceeding that  of the  myometrium  [17]. All  patients  underwent transvaginal  ultrasound(including  color  Doppler  imaging)  upon  admission,  and  the  fibroids  were  semi-quantitatively  graded based on blood supply in line with the following criteria: grade 0, no blood flow signal; grade  1, minimal blood flow with  1–2  punctate  signals;  grade  2,  moderate  blood flow with  one  main vessel  longer than the fibroid radius or 2–3 small vessels; grade 3, abundant blood flow with more than four interconnected vessels; and grade 4, extremely abundant blood flow with more than four reticular interwoven vessels or vessel diameter exceeding 3 mm.

 

Pretreatment preparation

Patients  in  both  the  H  and  H +P  groups  completed  laboratory  tests  to  confirm  their  compliance  with inclusion  and  exclusion  criteria. They were  required to follow  a  liquid  diet two  days  preoperatively  and take  laxatives  with  enema  administration  one  day  before  the  procedure.  On  the  day  of treatment,  the lower  abdomen  underwent  skin  preparation,  degreasing,  and  degassing,  followed  by  urinary  catheter placement. The  anesthesia  protocol  was  as  follows:  based  on  patient  weight,  fentanyl  and  midazolam were  administered  at  the  initial  intravenous  doses  of  1 μg/kg  and  0.03 mg/kg,  separately  followed  by supplemental  doses  of  0.8 μg/kg  and  0.02 mg/kg,   respectively,  after  30 min.  Subsequent  doses  were repeated at 30-min intervals at the same dosage. Throughout the procedure, patients tolerated treatment discomfort,  maintained  normal  cardiopulmonary  function,  and  responded  appropriately  to  verbal  and light tactile stimuli.

 

Treatment process

The  treatment  was  performed  using  the JC200  HIFU  system  (Chongqing  Haifu  Medical Technology  Co., Ltd., Chongqing, China) for  HIFU therapy. The system was  integrated with an  ultrasound  imaging device(MyLab  70,  Esaote,  Italy)  to  enable  real-time  treatment  guidance.  All  procedures  were  accomplished  in the  ultrasound  scanning  mode  with  a  slice  spacing  of 0.5 mm. The  parameters  of the  ultrasound  transducer  were  shown  below:  frequency  of  0.8 MHz,  diameter  of  200 mm,  focal  length  of  155 mm,  power range of 0–400 W, and  physical focal zone of  1.5 × 1.5 × 10 mm.  Patients  in the  H group were  placed  in a prone  position on the  HIFU treatment  bed, and electrocardiographic  monitoring and  intravenous access were  established.  Before  HIFU  treatment,  real-time  ultrasound  was  carried  out  to  localize  the  fibroid, ensuring  a  clear  acoustic  pathway  and  avoiding  intestinal  injury.  A  treatment  plan  was  subsequently formulated  with  the  power  being  set  at  400 W  in  the  point-scanning  mode. Treatment  completion  was determined  when  the  target  fibroid  area  exhibited  a  hyperechoic  patch  that  covered  the  entire  fibroid or significant grayscale enhancement.

For  patients  in  H +P  group,  ultrasound-guided  polidocanol  foam  injection  was  performed  prior  to HIFU ablation. The  specific  procedure was as follows.  For  sclerosant  preparation, a  1%  polidocanol  solution (Xi’an Tianyu Pharmaceutical Co., Ltd., China) was used. The polidocanol dosage was calculated using the formula  V =4/3π(r+0.5)³, where V  represents the total dose and  r denotes the  lesion  radius  in centimeters. To produce the foam, half of the calculated polidocanol solution was mixed with air at a 1:1 ratio. The Tessari  method  was  employed  to  prepare  the  sclerosing  foam. To  be  specific,  a  10 ml  syringe  containing  1%  polidocanol solution was connected to a  10 ml syringe containing an equal volume of room air  via  a  three-way  stopcock,  achieving  a  liquid-to-air  ratio  of  1:1 . Thereafter,  these  two  syringes  were rapidly  alternated  more  than  20  times  to  form  a  uniform,  fine-textured  foam. The  prepared  foam  was highly  stable  and  injected within  90 s to  ensure the  optimal  efficacy. With  regard to the  injection technique,  under continuous  real-time  ultrasound guidance, a  17 G  PTC  needle was  percutaneously or transvaginally  inserted  into  the  target  area  of the  uterine  fibroid.  Notably,  the  puncture  path  was  carefully planned to avoid critical structures such as the intestines and  major  blood vessels. Afterwards,  based on pretreatment  color  Doppler  ultrasound  findings,  the  needle  tip  was  positioned  within  the  peripheral region  of the  lesion  and/or  areas  with  abundant  blood  flow  signals.  For  site  distribution  and  injection dosage, a fan-shaped distribution strategy was adopted to administer polidocanol and  polidocanol foam at  multiple  sites  within  the  fibroid,  ensuring  extensive  coverage  of the  vascular  network. The  injection volume  was  adjusted  according  to  the  agent  diffusion  range  within  the  fibroid.  The  maximum  foam volume  per treatment  session was  set  at  15 ml,  and the  maximum  drug  dose  should  not  exceed  30 ml. Aspiration  was  performed  before  each  injection,  so  as  to  confirm  that  the  needle  tip  was  not  inside  a blood vessel.  During  perioperative  monitoring,  patients were closely  monitored throughout the injection procedure for adverse  reactions,  including  but  not  limited to changes  in  heart  rate,  blood  pressure, oxygen saturation, and signs of allergic reactions. Emergency medications and equipment were readily available. Within  1-h  postpolidocanol  injection,  the  H +P  group  underwent  HIFU  treatment  identical  to  that administered to the  H group.  Parameters  including  HIFU treatment duration,  procedural time, treatment intensity, and energy dose were  recorded for  patients  in the two groups.

 

Post-HIFU procedure evaluation

All patients underwent immediate on-board ultrasound measurement of the three-dimensional diameters of the  fibroid  (longitudinal  diameter  (d1),  longitudinal  diameter  (d2),  and  transverse  diameter  (d3))  following  HIFU  treatment.  Over  5 min  after  HIFU  completion,  1.5 ml  of  reconstituted  SonoVue  (each  vial containing 25 mg of SonoVue, Bracco, Milan, Italy, which was mixed with 5 ml of saline) was administered intravenously.  Two  min  later,  the  NPV  was  assessed  and  measured  through  on-board  ultrasound.  The volumes of both the fibroid and the  NPV were calculated  using the formula V =  (d1 ×d2 ×d3) × 0.5233. The  primary  efficacy  endpoint  was  the  non-perfused  volume  ratio  (NPVR%),  which  was  calculated  by(non-perfused volume/initial fibroid volume) ×  100%. To  reflect the clinical  relevance, the  primary  binary outcome was defined as the proportion of patients achieving technical success (an NPVR ≥ 80%). Whereas a  more  stringent  secondary  outcome  was  set  as  the  proportion  of  patients  achieving  an  NPVR  ≥  90%. Success  rate  refers to the  proportion of patients  immediately achieving the  predefined technical success criteria  (NPVR  ≥ 80%) or the  more stringent secondary criteria  (NPVR  ≥ 90%)  post-treatment.

 

Evaluation of side effects

The maximum VAS Pain score (0–10) and skin assessment were documented in nursing records. According to  the  Society  of  Interventional  Radiology  procedure,  side  effects  were  classified  as  grades  A–F  [9].  All adverse events were monitored and then recorded during the HIFU procedure and throughout the postoperative  inpatient  observation  period. After the treatment,  patients were  monitored  in the  HIFU  monitoring ward for at  least 24 h and discharged only after  being assessed as stable. As a  result, the adverse events  reported  in this study  reflect the short-term safety  profile  in the  perioperative  period.

In addition, this study specifically  monitored the  potential adverse reactions directly associated with the polidocanol injection procedure in the combination therapy group (H +P group), covering the period from the start of the injection until immediately before the subsequent HIFU treatment. The   monitoring  focused  on  allergic   reactions   (such  as   rash  and  dyspnea),  cardiovascular   responses(including  significant fluctuations  in  heart  rate  or  blood  pressure),  and  potential  complications theoretically associated with  inadvertent  intravascular  injection.

 

Statistical analysis

SPSS  27.0  software  (SPSS  Inc.,  Chicago,  IL,  USA)  and  R  software  (version  4.2.2)  were  employed  for statistical  analyses.  Categorical variables were  expressed  as frequencies,  and  between-group  comparisons for  binary  outcomes were  presented as  n/N  (%). Continuous variables were  described as  median(interquartile  range,  IQR)  or  mean ±standard  deviation.  Normality  of data was first  assessed  using the Kolmogorov-Smirnov  test. Then,  normally  distributed  quantitative  variables  were  analyzed  by  t-tests, while    non-normally    distributed    variables    were    analyzed    with    the    Mann-Whitney    U    test.    For between-group comparisons, categorical variables were evaluated  by chi-square tests or  Fisher’s exact probability test (by Yates-corrected χ2  test when all the expected frequencies were ≥ 5; and by  Fisher’s exact test at the expected frequencies  < 5). A  logistic  regression  model was  utilized to identify factors influencing  an  NPVR  ≥  80%  and  sacrococcygeal  pain.  Moreover,  propensity  scores  were  calculated through  logistic  regression  based  on  demographic and  clinical  characteristics, followed  by  1:1  nearest neighbor  matching  using the  MatchIt  package  in  R to  minimize the total absolute distance across the matched  pairs,  with  a  caliper  value  of  0.2.  This  ensured  covariate  balance  between  the  matched groups   (all   the   standardized   differences   <   10%).   A   P-value   <   0.05   was   considered   statistically significant.

 

Results

Patient characteristics

A total of 116 patients were enrolled for analysis, including 63 in the H group and 53 in the H +P group. Following  propensity score  matching, a total of 106  patients with fibroids were included in the  matched cohort,  including  53  (50%)  in the  H  group and  53  (50%)  in the  H +P  group.  Figure  1  shows the  patient flow diagram. Differences in age, BMI, uterine position, rectus abdominis muscle thickness, subcutaneous fat  layer  thickness,  distance  from  the  posterior  aspect  of fibroids  to  the  sacrococcyx,  ultrasound  blood flow  grading,  fibroid  type,  fibroid  location,  and  fibroid  volume  did  not  show  any  statistical  significance between the two groups  (p>0.05, Table  1).

 

Treatment parameters

All  patients  successfully  completed  the  ultrasound  ablation  therapy. The  median  sonication  time  in  the H +P  group was  significantly  shorter than that  in the  H  group  (578 s  [IQR:  399–745] vs.  758 s  [IQR: 408–1128];  p =0.022).  The  median  total  energy  delivered  was  also  significantly  lower  in  the  H +P  group(226,800 J  [IQR:  157,560–298,200] vs.  303,200 J  [IQR:  163,200–451,200]; p =0.013).  However,  there  was  no significant difference in the total operation time or treatment intensity between the two groups (p>0.05, Table  2).

 

Comparison of NPV outcomes

The  H +P group showed significantly superior  NPV outcomes to the  H group. To  be specific, the  median NPVR  was  higher  in  the  H +P  group  (92.57%  vs  77.81%,  p <0.001).  With  regard  to  the  primary  binary outcome  (an  NPVR  ≥  80%),  the  success  rates  were  89%  in  the  H +P  group  versus  43%  in  the  H  group(p <0.001).  For the secondary outcome  (an  NPVR  ≥ 90%), the success  rates were 60%  in the  H +P group versus 9%  in the  H group  (p <0.001, Table 3).

 

Figure  1.  patient enrollment flowchart.


Table  1.  patient demographics and  baseline characteristics.

Table  2.  Comparison of therapeutic  parameters  between  H group and  H + p group



Table 3.  Comparison of NPV  rates  between the two groups of patients.




Univariate and multivariate analyses of factors influencing an NPVR  ≥ 80%

In the univariate analysis, treatment modality was the only factor significantly associated with an NPVR ≥ 80%. Compared with patients receiving HIFU alone, those who received combined HIFU and polidocanol treatment were  significantly  more  likely  to  achieve  an  NPVR  ≥  80%  (OR  =  8.57,  95%  CI:  3.27–22.45, p <0.001).  Other factors,  including  age,  BMI,  uterine  position,  ultrasound  blood  flow  grading,  type  of  fibroids,  location  of fibroids, and fibroid volume, were  not significantly associated with the outcome.  In the  multivariate analysis, after adjusting for all the included covariates, the  HIFU +polidocanol treatment remained a strong and independent predictor of an NPVR ≥ 80% (adjusted OR =  15.13, 95% CI: 4.66–49.12, p <0.001, Table 4).

 

Table 4.  univariate and  multivariate analysis of influencing  NPVR  ≥80% factors.

 

Table 5.  Incidence  rate of adverse effect during  HIFU treatment.

 

Safety of polidocanol injection

Throughout  the  H +P  group  (n =53),  no  adverse  reactions  directly  attributable  to  polidocanol  injection were  reported  during  the  monitored  interval  (from  the  start  of  injection  until  immediately  before  HIFU treatment).

Adverse events  (AEs) during HIFU treatment

The  incidence  and  severity  of AEs  during  HIFU  treatment  are  summarized  in Table  5.  As  observed,  the overall  incidence  of  AEs  was  comparable  between  the  H  group  (73.6%)  and  the  H +P  group  (69.8%)(p =0.506). The profile of minor AEs (SIR Grade A), including abdominal pain, skin discomfort, pain in the groin area,  nerve stimulation, and fever, was  largely similar  between the two groups  (p>0.05).  However, there was a statistically significant difference in the incidence of sacrococcygeal pain, which was reported in  24  patients  (45.3%)  in  the  H  group  whereas  only  in  3  patients  (5.7%)  in  the  H +P  group  (p <0.001). Moderate AEs  (SIR  Grade  B) were  rare.  One  case  of heavier abdominal  pain  and  lower  extremity  numbness  was  reported  in  the  H  group,  while  such  events  were  not  reported  in  the  H +P  group,  and  the differences were  not statistically significant  (p = 1.000).  No severe AEs  (SIR Grades C-F) or vascular embolism events occurred  in either group.

Table 6.  univariate and  multivariate analysis of influencing sacrococcygeal  pain factors.

 

Risk factors for sacrococcygeal pain

In  univariate  analysis,  retroverted  uterus  (OR  = 4.24,  95%  CI:  1.67–10.78, p =0.002), treatment with  HIFU alone (reference: HIFU +polidocanol; OR = 0.07, 95% CI: 0.02–0.26, p <0.001), and a shorter distance from the  fibroid  to  the  sacrococcyx  (OR  =  0.96,  95%  CI:  0.93–1.00, p =0.028)  were  the  significant  risk factors for sacrococcygeal  pain.  In the  multivariate  model, after adjusting for confounding variables,  both  retroverted uterus and treatment type remained the independent and significant predictors of sacrococcygeal pain.  Moreover,  the  odds  of  the  event  was  substantially  higher  for  patients  with  a  retroverted  uterus(adjusted OR = 9.77, 95% CI: 2.40–39.73, p =0.001). Conversely, the HIFU +polidocanol treatment remained a strong  protective factor  (adjusted OR = 0.03, 95% CI: 0.01–0.17, p <0.001, Table 6).

Discussion

This  retrospective  analysis  suggested  that  the  combination  of  intratumoral  polidocanol  injection  and HIFU might enhance the immediate treatment efficacy for T2-hyperintense uterine fibroids. The observed superior NPVR and reduced energy requirements in the H +P group warrant further investigation. Notably, the  H +P  group demonstrated a  lower  incidence  of sacrococcygeal  pain, though  retrospective  data  preclude causal attribution.

NPVR  serves  as  a  critical  predictor for  HIFU  outcomes.  Prior  evidence  has  indicated  that  the  NPVR  >80%  is  correlated with  improved volume  reduction  and  reduced  reintervention  rates  [5,8].  Prior to  HIFU ablation,  MRI  has  become  an  essential  tool  for  predicting  and  assessing  the  fibroid  treatment  efficacy, with T2WI  signal  intensity  being the  most  pivotal  indicator of HIFU effectiveness  [3,18–20].  Due to their higher cellularity,  lower collagen content, abundant fluid, and  heightened vascularization, these features impede  ultrasonic  energy  deposition  [3,11,19].  A  retrospective  study  involving  339  patients  reported  a median NPVR of 75.2% (IQR: 31.5%) for hyperintense fibroids [21]. Our findings aligned with these results: among the  53  patients with T2WI  hyperintense fibroids treated with  HIFU  alone, the  median  NPVR was77.8%,  suggesting  that  it  remains  challenging  to  achieve  an  NPVR  of 80%  with  the  current  HIFU  technology for such fibroids.

Multiple  studies  have  demonstrated  that  sulfur  hexafluoride  microbubbles  can  safely  enhance  and accelerate  HIFU  ablation  for  uterine  fibroids  [22,23].  Research  exploring  the  feasibility  of  combining HIFU  with   ultrasound-guided   intratumoral   ethanol   injection   has   reported   improved   ablation   rates, shorter  procedure times,  lower energy doses, and significant  reductions in  patient  pain and side effects[9].  However,  none of these studies address the outcomes for T2WI  hyperintense fibroids. As suggested in  a  propensity  score-matched  cohort  study,  GnRH-a  pretreatment  combined  with  HIFU  may  improve the  efficacy  for  heterogeneous T2WI  hyperintense  fibroids  [11,21].  Nevertheless,  the  GnRH-a  combination  therapy  presents  drawbacks,  where  the  insufficient  estrogen  levels  may  trigger  severe  perimenopausal  symptoms,  leading  to  treatment  discontinuation  and  compromised  efficacy  [21].  Additionally, this  regimen  requires  a  3-cycle  GnRH-a  pretreatment,  prolonging  the  overall  treatment  duration  [11]. Thus,  it  is  imperative  to  explore  novel  strategies  to  improve  the  NPVR  for T2WI  hyperintense  fibroids. Our study demonstrated that the combined therapy group achieved a significantly higher NPVR (92.57%), exceeding  the  efficacy  threshold  of  80%  in  89.8%  of  cases.  While  retrospective  studies  suggest  that increases  in   NPVRs   may   reduce  the   recurrence   risk   [7],  our  findings   require   prospective  validation regarding  the  long-term  symptom  relief. The  mechanism  underlying  the  improved  ablation  efficiency may  be  that,  polidocanol  foam  microbubbles  potentially  lower  the  cavitation  threshold,  facilitating energy  deposition  at  the   lower  acoustic   power   [10,24].   Sclerosant-induced  vascular  occlusion   may reduce the  heat-sink effects  [12,14].

Uterine  fibroids  are  a  key  focus  in  obstetrics  and  gynecology,  and  current  research  has  emphasized minimally invasive treatments. Patients with T2 hyperintense fibroids may benefit from this combined therapy, which offers a minimally invasive option while reducing drug-related adverse effects (e.g. menopausal symptoms and decreased bone density). In our study, the comparable overall adverse reaction rates (73.6% vs 69.8%) suggested no major safety concerns. The significantly lower sacrococcygeal pain incidence in the H +P group (5.7% vs 45.3%) merits attention, though confounding factors (like patient individual variation) cannot  be  excluded. Vascular  complications  theoretically  associated  with  sclerosants  were  not  observed, possibly due to  localized administration  [13]. Moreover, the absence of injection-related adverse events in the  H +P  group  suggests  that,  under  the  study  protocol  utilizing  ultrasound-guided  precise  intralesional injection,  polidocanol administration  itself exhibits a favorable  procedural safety  profile.

While the findings  are  encouraging,  several  limitations  in this  study  should  be  noted.  First,  although propensity    score    matching    and    multivariate    adjustments    were    employed    in    this    retrospective non-randomized  study  to  adjust  for  confounders,  there  are  still  risks  of selection  bias  and  unmeasured confounding due to  its  inherent  nature. Treatment allocation was  based on clinical judgment, and  residual  confounding  (such  as  subtle  variations  in  the  fibroid  texture  or  patient  anatomy  not  fully  captured by  the  variables)  may  persist,  even  though  key  baseline  characteristics  were  balanced  post-matching. Second,  fibroid  characterization  was  dependent  on  the  routine  clinical  MRI  sequences.  Considering  the absence of quantitative T2-weighted imaging analysis, it is impossible to further investigate the  relationship  between  specific  signal  intensity  values  and  ablation  efficacy.  Furthermore,  although  perioperative safety  profiles  were  favorable,  the  follow-up  period  was  limited  to  short-term  outcomes.  The  lack  of systematic  long-term  data,  including  fibroid  volume  reduction,  symptomatic  improvement,  and  recurrence  rates,  constrains  our  understanding  of  the  sustained  clinical  benefits  of  the  combined  therapy. Given  the  above-mentioned  limitations  and  the  preliminary  evidence  gathered,  future  studies  should prioritize  large-scale  prospective  randomized controlled trials.  Incorporating quantitative MRI parameters, such  as T2  mapping  and  perfusion  metrics, would  be  invaluable for  establishing  reliable  predictive  biomarkers for treatment success. Additionally, subsequent efforts should emphasize  long-term follow-up to assess  the  patient-centered  outcomes,  including  quality  of  life,  degree  of symptom  relief,  and  need  for reintervention.  Besides,  complementary  laboratory  studies  exploring  the  optimal  dosage  of  polidocanoland  its  underlying  biophysical  mechanisms  can  further  refine  the  treatment  protocol  and  enhance  our understanding of how sclerosants augment  HIFU ablation.

Conclusion

Retrospective  data  indicate  that  ultrasound-guided  intratumoral  polidocanol  combined  with  HIFU  may potentially  improve  the  immediate  ablation  efficiency  in  high-T2  signal  uterine  fibroids,  with  favorable energy  utilization and  pain outcomes.  Prospective studies are  needed to establish the  long-term clinical benefits.

Author contributions

This  research  was  developed  by  Ming-tao Yang,  Hui-quan  Hu,  Jun  Li,  and  Hong-ni  He,  and  carried  out  by  Chuan Lin,  Yu  Xia  and  Ling Tian.  Ming-tao  Yang  and Tian-wen  He  contributed  information  from  medical  records.  Jun  Li assisted  all  authors  in  drafting  the  original  manuscript. The  article’s  final  form  was  written  and  approved  by  all  of the writers.

Disclosure statement

No  potential conflict of interest was  reported  by the author(s).

Funding

This work was supported  by the  Project of Nanchong Science and Technology  Bureau  [Grant  number. 20SXQT0002],the  Foundation  of  State  Key  Laboratory  of  Ultrasound  in  Medicine  and  Engineering  [Grant  number.  2020KFKT003,2021KFKT022] and the  North Sichuan  Medical College Youth  Program  under Grant  [Grant  number. CBY23-QNA19].

ORCID

Ying Tang 

http://orcid.org/0000-0001-9318-8986

Data availability statement

The datasets generated and analyzed  in the current study are available from the corresponding author.

References

[1]   Giuliani  E,  As-Sanie  S,  Marsh  EE.  Epidemiology  and  management  of  uterine  fibroids.  Int  J  Gynaecol  Obstet.2020;149(1):3–9 . doi:  10.1002/ijgo.13102 .

[2]   Management  of  Symptomatic   Uterine   Leiomyomas:  ACOG   Practice   Bulletin,   Number  228.  Obstet  Gynecol.2021;137(6):e100–e115 .

[3]   Wang  L,  Liu  Y,  Lin  J,  et  al.  Effect  of  "T2-rim  sign"  related  parameters  on  high-intensity  focused  ultrasound ablation of uterine fibroids.  Eur J  Radiol.  2024;181:111767 . doi:  10.1016/j.ejrad.2024.111767 .

[4]   Li  W,  Jiang  Z,  Deng  X,  et  al.  Long-term  follow-up  outcome  and  reintervention  analysis  of  ultrasound-guided high intensity focused  ultrasound treatment for  uterine fibroids.  Int J  Hyperthermia. 2020;37(1):1046–1051 . doi:10.1080/02656736 .2020.1807617.

[5]   Yang  MJ,  Yu  RQ,  Chen  WZ,  et  al.  A  prediction  of  NPVR  ≥  80%  of  ultrasound-guided  high-intensity  focused ultrasound ablation for  uterine fibroids.  Front  Surg.  2021;8:663128 . doi:  10.3389/fsurg.2021.663128 .

[6]   Funaki K, Sawada K, Maeda F, et al. Subjective effect of magnetic resonance-guided focused ultrasound surgery for  uterine fibroids. J Obstet Gynaecol  Res.  2007;33(6):834–839 . doi:  10.1111/j.1447-0756.2007.00665.x.

[7]   Dou Y, Zhang  L,  Liu Y, et al.  Long-term outcome and  risk factors of reintervention after  high  intensity focused ultrasound   ablation   for    uterine   fibroids:   a   systematic    review   and    meta-analysis.    Int   J    Hyperthermia.2024;41(1):2299479 . doi:  10.1080/02656736 .2023.2299479.

[8]   Yang  M,  Chen Y,  Zhou  X,  et  al.  Machine  learning  models for  prediction  of  NPVR  ≥80% with  HIFU  ablation for uterine fibroids.  Int J  Hyperthermia.  2025;42(1):2473754 . doi:  10.1080/02656736.2025.2473754 .

[9]   Yang Z, Zhang Y, Zhang  R,  et al. A  case‐control  study  of high‐intensity focused  ultrasound  combined with  sonographically  guided  intratumoral  ethanol  injection  in  the  treatment  of  uterine  fibroids.  J  Ultrasound  Med.2014;33(4):657–665 . doi:  10.7863/ultra.33.4.657.

[10]   Farny CH, Glynn Holt R, Roy RA. The correlation between bubble-enhanced HIFU heating and cavitation power. IEEE Trans  Biomed  Eng.  2010;57(1):175–184 . doi:  10.1109/TBME.2009.2028133 .

[11]   Yang S, Kong F, Hou R, et al. Ultrasound guided high-intensity focused ultrasound combined with gonadotropin releasing  hormone  analogue  (GnRHa)  ablating  uterine  leiomyoma  with  homogeneous  hyperintensity  on T  (2) weighted  MR  imaging.  Br J  Radiol.  2017;90(1073):20160760 . doi:  10.1259/bjr.20160760 .

[12]   Min  X,  Zhang  Z,  Chen  Y,  et  al.  Comparison  of  the  effectiveness  of  lauromacrogol  injection  for  ablation  and microwave ablation in the treatment of predominantly cystic thyroid nodules: a multicentre study. BMC Cancer.2023;23(1):785 . doi:  10.1186/s12885-023-11301-7 .

[13]   Qi Y,  Huang Y. Treatment for abdominal wall endometriosis: ultrasound-guided percutaneous injection of lauromacrogol sclerotherapy. J  Minim  Invasive Gynecol.  2023;30(3):171–172 . doi:  10.1016/j.jmig.2022.12.009.

[14]   Qi  YF,  Dong  XQ,  Zhang  LW,  et  al.  Clinical  value  of  ultrasound-guided  lauromacrogol-assisted  radiofrequency ablation for uterine fibroids. Chinese Journal of Ultrasonography. 2016;32(11):1022–1024 . Retrieved from: https:// kns.cnki.net/kcms2/article/abstract v=yqBhao7Q9gxXndGPYvbNr7ihIZuCi-iEZT We-KcWY12_nuCPyPhRdsgV Xn3mB v ni2iST FW oL k uo yj m25Cb qx9JIG bKa E ep9J ZD2FT OrjG ll wsj Dd60tV L c d ks mm8Ygj9c2dZKJpH3zlRAGDn2d0UtIMBABKFxIsZgq-77jpUD0oWW29jUUlcg==&uniplatform=NZKPT&language=CHS

[15]   Chen Y,  Jiang  J,  Zeng Y,  et  al.  Effects  of  a  microbubble  ultrasound  contrast  agent  on  high-intensity  focused ultrasound  for  uterine  fibroids:  a  randomised  controlled  trial.  Int  J  Hyperthermia.  2018;34(8):1311–1315 .  doi:10.1080/02656736 .2017.1411620.

[16]   Funaki  K,  Fukunishi  H,  Funaki T,  et  al.  Magnetic  resonance-guided  focused  ultrasound  surgery  for  uterine  fibroids:  relationship  between  the  therapeutic  effects  and  signal  intensity  of  preexisting T2-weighted  magnetic resonance  images. Am J Obstet Gynecol.  2007;196(2):184.e181-186–184.e6 . doi:  10.1016/j.ajog.2006.08.030 .

[17]   Ueda  H, Togashi  K,  Konishi  I, et al.  Unusual appearances of uterine  leiomyomas: MR imaging findings and their histopathologic  backgrounds.   Radiographics.   1999;19  Spec   No(suppl_1):S131–S145 .  doi:   10.1148/radiographics.19.suppl_1.g99oc04s131 .

[18]   Zhao WP,  Chen  JY,  Zhang  L,  et  al.  Feasibility  of  ultrasound-guided  high  intensity  focused  ultrasound  ablating uterine  fibroids  with   hyperintense   on  T2-weighted   MR   imaging.   Eur  J   Radiol.   2013;82(1):e43-49–e49 .   doi:10.1016/j.ejrad.2012.08.020 .

[19]   Zhao  WP,  Zhang  J,  Han  ZY,  et  al.  A  clinical  investigation  treating  different  types  of  fibroids  identified  by MRI-T2WI  imaging  with  ultrasound  guided  high  intensity  focused  ultrasound.  Sci  Rep.  2017;7(1):10812 .  doi:10.1038/s41598-017-11486-5 .

[20]   Rio G,  Lima M, Gil  R, et al. T2  hyperintense myometrial tumors: can MRI features differentiate  leiomyomas from leiomyosarcomas  Abdom  Radiol  (NY).  2019;44(10):3388–3397 . doi:  10.1007/s00261-019-02097-x.

[21]   Jiang  L, Yu JW, Yang MJ, et al.  Ultrasound-guided  HIFU for  uterine fibroids of hyperintense on T2-weighted MR imaging  with  or  without  GnRH-analogue-pretreated:  A  propensity  scores  matched  cohort  study.  Front  Surg.2022;9:975839 . doi:  10.3389/fsurg.2022.975839 .

[22]   Jin J, Zhao Y,  Huang  P. Combination of HIFU with sulfur  hexafluoride  microbubbles in the treatment of solitary uterine   fibroids:   a   systematic   review   and   meta-analysis.   Eur   Radiol.   2024;34(6):3786–3794 .   doi:   10.1007/ s00330-023-10407-7 .

[23] [23]   Yao  R,  Zhao W,  Gao  B,  et  al.  Microbubble  contrast  agent  SonoVue  combined with  oxytocin  improves the  efficiency of high-intensity focused ultrasound ablation for adenomyosis. Int J Hyperthermia. 2021;38(1):1601–1608 . doi:  10.1080/02656736 .2021.1993357.

[24] [24]   Chen  C,  Liu Y,  Maruvada  S,  et  al.  Effect  of  ethanol  injection  on  cavitation  and  heating  of tissues  exposed  to high-intensity focused  ultrasound.  Phys  Med  Biol.  2012;57(4):937–961 . doi:  10.1088/0031-9155/57/4/937.


Copyright 2019-2020 中国硬化网 all rights reserved 陕ICP备08100338号-2
Top